Onco-Innovations Limited
ONCO
CNSX
| 10/31/2024 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 10.41% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 11.93% | ||||
| Operating Income | -11.93% | ||||
| Income Before Tax | 42.70% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 42.70% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 42.70% | ||||
| EBIT | -11.93% | ||||
| EBITDA | -- | ||||
| EPS Basic | 48.53% | ||||
| Normalized Basic EPS | 48.84% | ||||
| EPS Diluted | 48.53% | ||||
| Normalized Diluted EPS | 48.84% | ||||
| Average Basic Shares Outstanding | 13.21% | ||||
| Average Diluted Shares Outstanding | 13.21% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||